Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

167.25 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,192
Open 167.25
Bid (Size) 163.01 (1)
Ask (Size) 167.24 (1)
Prev. Close 167.25
Today's Range 167.25 - 167.25
52wk Range 125.82 - 335.91
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
7 Stable Stocks for 50% Returns by Early 2025
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries. 
Via InvestorPlace

Performance

YTD
-20.02%
-20.02%
1 Month
+1.52%
+1.52%
3 Month
-16.87%
-16.87%
6 Month
+19.77%
+19.77%
1 Year
-47.95%
-47.95%

More News

Read More
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
From Insulet Corporation
Via Business Wire
Analyst Scoreboard: 5 Ratings For Insulet
Via Benzinga
Insulet: Q4 Earnings Insights
Via Benzinga
Should you consider NASDAQ:PODD for growth investing?
Via Chartmill
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Via Talk Markets
5 Stocks To Buy On The Dip To Gain From The Wall Street Rally
Via Talk Markets
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
From Insulet Corporation
Via Business Wire
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Are These 5 Undervalued Stocks Ready to Break Out?
Via MarketBeat
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
From Insulet Corporation
Via Business Wire
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
From Insulet Corporation
Via Business Wire
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Via Benzinga
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
DexCom: A Winner In Diabetes Management
Via Talk Markets
Nasdaq, S&P 500 Set for Mixed Open After Nvidia Euphoria: Analyst Picks Major Market Catalyst This Year If There Are No Rate Cuts
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
From Insulet Corporation
Via Business Wire
Nasdaq, S&P 500 Futures Jump As Nvidia Surge Raises 'FOMO' Rally Hopes: Analyst Tells Why Jobs Data Holds Key For Momentum
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
From Insulet Corporation
Via Business Wire
Earnings Scheduled For February 22, 2024
Via Benzinga
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
From Insulet Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.